Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


P&G’s Intrinsa For Female Sexual Dysfunction To Get Cmte. Review Dec. 2

This article was originally published in The Pink Sheet Daily

Executive Summary

If recommended by FDA’s Reproductive Health Drugs Advisory Committee, Intrinsa would be on a path for approval in December or January. The testosterone patch could be the first treatment for female sexual dysfunction.

You may also be interested in...

P&G's Intrinsa Priority Review Puts Approval Timeline At Early 2005

NDA for testosterone patch to treat reduced sexual desire in surgically menopausal women was submitted in early summer. First female sexual dysfunction agent filed at FDA is "next major opportunity" for P&G's pharmaceutical business, CFO Daley tells Banc of America Securities conference.

FDA Antihypertensive Draft Class Labeling To Be Reviewed By Cardio-Renal Committee

FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.

Bristol Sprycel For Gleevec-Resistant Leukemia To Get Committee Review At June ASCO Meeting

FDA’s Oncologic Drugs Advisory Committee will meet in Atlanta to review Bristol’s multi-targeted kinase inhibitor dasatinib for two leukemia indications.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts